MSS51

MSS51 (ZMYND17) is a mitochondrial protein whose function has diverged between yeast and mammals: in yeast it couples cytochrome c oxidase (CcO) assembly to COX1 mRNA translation, while in mammals it acts as a negative regulator of mitochondrial respiration, fatty acid β-oxidation, and glycolysis in skeletal muscle. In Saccharomyces cerevisiae, Mss51 serves as a translational activator of COX1 mRNA via its 5′-UTR and is post-translationally sequestered in a Cox1–Cox14–Cox25–Ssc1–Mss51 assembly intermediate, creating a homeostatic feedback loop that limits Cox1 synthesis until CcO assembly proceeds (PMID:2177521, PMID:19710419, PMID:21068384). In mammals, MSS51 does not regulate mitochondrial translation but instead constrains oxidative phosphorylation and cytochrome c oxidase activity; its genetic ablation in mice increases myofiber oxygen consumption, β-oxidation, and insulin sensitivity, conferring resistance to diet-induced obesity (PMID:31527314, PMID:34565318). MSS51 expression is transcriptionally repressed by Yy1 and post-transcriptionally destabilized by YTHDF2, and it functions downstream of TGF-β1/Site-1 protease signaling to restrain muscle mitochondrial metabolism (PMID:39187977, PMID:37002920, PMID:38830447).

1. 1990 High

   Establishing that Mss51 is a COX1-specific translational activator linked to the mitoribosome resolved its primary molecular function in yeast mitochondria.

   Evidence Genetic analysis of mss51 mutants and paromomycin-resistance suppressor mutations in 15S rRNA in S. cerevisiae

   PMID:2177521

   Open questions at the time

   • No biochemical interaction with the ribosome or COX1 mRNA demonstrated
   • Mechanism of translational activation unknown
2. 2009 High

   Demonstrating that Mss51 has a dual function — translational activation and post-translational chaperoning of Cox1 — and that its sequestration in Cox14-dependent assembly intermediates feeds back to limit COX1 translation established the homeostatic coupling mechanism between Cox1 synthesis and CcO assembly.

   Evidence Reciprocal co-immunoprecipitation of Mss51 with Cox1 assembly intermediates, reporter gene assays, and genetic epistasis in cox14 and other assembly mutants in S. cerevisiae

   PMID:19710419

   Open questions at the time

   • Structural basis of Mss51–Cox1 interaction unknown
   • How Mss51 is released from assembly intermediates upon CcO maturation not defined
3. 2010 High

   Identifying Cox25 as an essential component of the Cox1–Ssc1–Mss51–Cox14 intermediate that bridges to downstream Shy1/Cox5-containing complexes defined the compositional architecture of the early CcO assembly pathway.

   Evidence Co-immunoprecipitation, subcellular fractionation, and genetic epistasis analysis in S. cerevisiae

   PMID:21068384

   Open questions at the time

   • Stoichiometry of the intermediate not determined
   • Mechanism of handoff from Mss51-containing to Shy1-containing complexes unclear
4. 2015 Medium

   Localizing mammalian MSS51 to skeletal muscle mitochondria and showing that its disruption increases ATP production, β-oxidation, and oxidative phosphorylation revealed a functional divergence from yeast — MSS51 acts as a metabolic brake rather than a translational activator.

   Evidence Subcellular fractionation and CRISPR/Cas9 knockout in C2C12 myoblasts with Seahorse metabolic profiling

   PMID:26634192

   Open questions at the time

   • Direct molecular target through which MSS51 constrains respiration not identified
   • Single cell line study
5. 2018 High

   In vivo knockout of Zmynd17 demonstrated that MSS51 is required for normal mitochondrial morphology and that its loss causes metabolic stress, hepatic steatosis, and insulin resistance under dietary challenge, establishing systemic metabolic consequences.

   Evidence Zmynd17-KO mice with electron microscopy, oxygen consumption measurements, and high-fat diet metabolic challenge

   PMID:29913553

   Open questions at the time

   • Paradox between increased respiration in myofibers and metabolic stress phenotype not fully resolved
   • Whether mitochondrial morphology defects are primary or secondary unclear
6. 2019 High

   Independent Mss51-KO mice confirmed that MSS51 loss increases myofiber oxygen consumption and β-oxidation gene expression, and demonstrated protection from diet-induced obesity with improved glucose homeostasis, solidifying MSS51 as a druggable negative regulator of muscle metabolism.

   Evidence CRISPR/Cas9 Mss51-KO mice with Seahorse on isolated myofibers, hyperinsulinemic-euglycemic clamp, and metabolic phenotyping

   PMID:31527314

   Open questions at the time

   • Molecular mechanism of metabolic suppression still undefined
   • Discrepancy with Zmynd17-KO steatosis phenotype not reconciled
7. 2019 Medium

   Epistasis experiments showed that Zmynd17 and PGC1α control mitochondrial quality through independent pathways, since PGC1α overexpression worsened mitochondrial morphology in Zmynd17-KO muscle, distinguishing MSS51 from canonical biogenesis programs.

   Evidence Zmynd17-KO mice crossed with PGC1α-overexpressing mice, voluntary exercise, electron microscopy

   PMID:31921843

   Open questions at the time

   • Pathway through which MSS51 maintains mitochondrial morphology unknown
   • Single morphological readout
8. 2021 Medium

   Deletion of ZMYND17 in human cells did not affect mitochondrial translation but reduced cytochrome c oxidase activity and increased free F1 ATP synthase subunits, confirming mammalian MSS51 has functionally diverged from the yeast translational activator role.

   Evidence ZMYND17 gene deletion in human cells with mitochondrial translation assay, CcO activity measurement, and immunoblot

   PMID:34565318

   Open questions at the time

   • Single lab, low citation count
   • Whether CcO activity reduction is direct or indirect not established
   • Mechanism of F1 accumulation unexplained
9. 2023 Medium

   Placing MSS51 downstream of Site-1 protease in a TGF-β1 signaling axis — where S1P loss reduces Mss51 expression and MSS51 overexpression rescues the metabolic phenotype — defined the first upstream signaling pathway controlling MSS51-mediated metabolic suppression.

   Evidence Muscle-specific S1P knockout mice with Mss51 overexpression rescue, oxygen consumption rate measurements

   PMID:37002920

   Open questions at the time

   • Intermediate signaling steps between S1P/TGF-β1 and Mss51 transcription not mapped
   • Single lab
10. 2024 Medium

    Two independent studies defined transcriptional and post-transcriptional regulation of MSS51: Yy1 directly binds the Mss51 promoter to repress transcription, and YTHDF2 binds MSS51 mRNA to promote its degradation, linking MSS51 levels to m6A-dependent RNA decay and aging-associated superoxide control.

    Evidence ChIP, EMSA, and luciferase reporter for Yy1–Mss51 promoter binding in C2C12 and aging mouse muscle; RNA immunoprecipitation for YTHDF2–MSS51 mRNA in human granulosa cells

    PMID:38830447 PMID:39187977

    Open questions at the time

    • Relative contributions of transcriptional vs. post-transcriptional control in physiological settings unknown
    • YTHDF2 regulation shown only in granulosa cells, not in muscle

• The direct molecular target or mechanism through which mammalian MSS51 constrains mitochondrial respiration remains unknown — whether it acts as a chaperone, assembly factor, or signaling scaffold has not been resolved.
• No binding partner or substrate identified for mammalian MSS51's inhibitory function
• No structural information available for MSS51 in any species
• Discrepancy between two KO mouse models (obesity resistance vs. steatosis) unresolved